Granules India Limited has announced that Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company located in Chantilly, Virginia, USA had undergone a PreApproval Inspection (PAI) audit by the U.S. Food and Drug Administration (FDA) from 21st June 2021 to 25th June 2021. The audit is a pre-approval inspection for three of its applications filed from this facility. The FDA issued two minor observations during the audit.
"The observations were responded to within the stipulated time, and we are happy to inform that the FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021. This is the fifth US FDA audit for this facility" said Ms. Priyanka Chigurupati, Executive Director, GPI.
Shares of GRANULES INDIA LTD. was last trading in BSE at Rs.368 as compared to the previous close of Rs. 377.7. The total number of shares traded during the day was 215469 in over 3825 trades.
The stock hit an intraday high of Rs. 381.1 and intraday low of 360.25. The net turnover during the day was Rs. 79652312.